Tissue lipocalin-2 in psoriasis: is it a marker of metabolic disturbance or a possible marker of therapeutic efficacy after narrow band ultraviolet B?

Hay, Rania Abdel; Samir, N.; Safwat, Marwa; Rashed, Laila; Solimán, M. K.

doi:10.1080/09546634.2019.1605141

Cited by 9 publications

(8 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the clinical setting, tissue LCN2 was found to be also significantly higher in psoriasis, regardless of dyslipidemia, or metabolic disturbance in patients. But the LCN2 levels together with psoriasis area and severity index (PASI) score significantly dropped after NBUVB treatment (143). The in vivo effects of LCN2 on topical imiquimod (IMQ)-induced psoriasis-like skin in BALB/c mice were evaluated by Hau group (138).…”

Section: Nets and Psoriasismentioning

confidence: 99%

Neutrophils in Psoriasis

et al. 2019

View full text Add to dashboard Cite

Neutrophils are the most abundant innate immune cells. The pathogenic roles of neutrophils are related to chronic inflammation and autoimmune diseases. Psoriasis is a chronic systemic inflammatory disease affecting ∼2-3% of the world population. The abundant presence of neutrophils in the psoriatic skin lesions serves as a typical histopathologic hallmark of psoriasis. Recent reports indicated that oxidative stress, granular components, and neutrophil extracellular traps from psoriatic neutrophils are related to the initial and maintenance phases of psoriasis. This review provides an overview on the recent (up to 2019) advances in understanding the role of neutrophils in the pathophysiology of psoriasis, including the effects of respiratory burst, degranulation, and neutrophil extracellular trap formation on psoriatic immunity and the clinical relationships.

show abstract

Section: Nets and Psoriasismentioning

confidence: 99%

Neutrophils in Psoriasis

et al. 2019

View full text Add to dashboard Cite

show abstract

“… 13 For example, it was recognized that phototherapy with narrowband ultraviolet B (NBUVB) exerts its therapeutic function by decreasing the expression of lipocalin 2 in psoriatic lesions. 24 Recently, it was found that methyl 4-(adenin-9-yl)-2-hydroxybutanoate (DZ2002) inhibits psoriatic inflammation by regulating the DNA methylation of the lipocalin 2 promoter, which further confirmed the therapeutic role of lipocalin 2 in psoriasis. 67 Moreover, it has been proved that neutralizing Tcf7l1 attenuates keratinocyte apoptosis and alleviates the effect of neutrophil aggregation and keratinocyte proliferation by decreasing lipocalin 2 and other downstream cytokines.…”

Section: Diagnostic and Therapeutic Strategies Based On Lipocalin 2 S...mentioning

confidence: 90%

“…Several studies have shown that lipocalin 2 levels are elevated in the skin lesions and serum of patients with psoriasis, and lipocalin 2 has been proved to be effective in regulating inflammation and cell proliferation in psoriasis. 24 There has been a large number of articles highlighting lipocalin 2ʹs versatile functions, such as being an indicator for predicting the prognosis and mortality of neoplasms and psoriasis. However, there are few convincing pieces of evidence that highlight the diagnostic and treatment value of lipocalin 2.…”

Section: Introductionmentioning

confidence: 99%

Lipocalin 2 Participates in the Epidermal Differentiation and Inflammatory Processes of Psoriasis

Ren

Xia

2022

JIR

View full text Add to dashboard Cite

As a multifunctional cytokine, lipocalin 2 is weakly expressed in skin and serum under normal conditions. However, it is over-expressed by neutrophils and keratinocytes in the skin lesions and sera in several skin diseases. Recent studies demonstrated that lipocalin 2 participates in the pathogenesis of psoriasis by exerting versatile effects on skin resident cells and infiltrating immune cells. Lipocalin 2 inhibits the synthesis of keratin, involucrin, and loricrin in keratinocytes, leading to epidermal parakeratosis via the Tcf7l1-lipocalin 2 signaling axis. It also recruits inflammatory cells such as T cells and neutrophils into skin lesions via the IL-23/IL17, p38-MAPK, and ERK-1/2 signaling pathways. Additionally, lipocalin 2 and other cytokines such as IL-17 have the synergetic effects on skin cells. The neutralization of lipocalin 2 or relevant cytokines can alleviate psoriasis, verifying that lipocalin 2 is an effective interfering target for psoriasis. In this review, we summarize the roles of lipocalin 2 in the processes of psoriatic inflammation and the promising therapeutic strategies based on lipocalin 2-related molecules.

show abstract

“…More than 20 biomarkers of metabolic syndrome in patients with psoriasis have been reported in the literature at the gene or protein expression level, including cluster of differentiation-5 molecule-like C-reactive protein, 17 E-selectin, 18 endocan, 19 galectin-3, 20 intercellular adhesion molecule-1, 21 interleukin-17, 22 insulin, 23 lipocalin-2, 24 liver fatty acid-bindingprotein, 25 matrix metalloproteinase-2, 21 matrix metalloproteinase-9, 21 pentraxin-3, 26 plasminogen activator inhibitor type-1, 18 platelet endothelial cell adhesion molecule-1, 18 resistin, 21 tumor necrosis factor-α, 19 vaspin, 21 and vascular cell adhesion molecule-1, 18 , 21 adipocyte fatty acid-binding protein, 27 and adiponectin and visfatin, 21 with an FC ranging from 1.21 for vascular cell adhesion molecule-1 (a marker of vascular damage that is also increased in patients with diabetes mellitus) to 26.6 for cutaneous lipocalin-2 (a molecule associated with insulin resistance, obesity, and atherosclerosis).…”

Section: Discussionmentioning

confidence: 99%

Upregulation of REL and WSB1 in patients with psoriasis and metabolic syndrome

Alsabbagh¹,

Bakhiet²,

Taha³

2023

International Journal of Dermatology and Venereology

View full text Add to dashboard Cite

Objective: A strong association exists between metabolic syndrome and psoriasis. The current study was performed to explore the gene regulation of metabolic syndrome in patients with psoriasis.Methods: Patients were assessed for psoriasis and metabolic syndrome clinically (Psoriasis Area and Severity Index, height, weight, waist circumference, and blood pressure) and biochemically (lipid profile and fasting blood sugar concentration). Systemic gene regulation was first explored by microarray and analyzed using Transcriptome Analysis Console Software, after which two selected upregulated genes were further validated using polymerase chain reaction and enzyme-linked immunosorbent assay and analyzed using independent sample t test.Results: The analysis showed 7,269 upregulated and 3 downregulated genes at a fold change of 2 and P value of < 0.05; only 17 genes were upregulated and none were downregulated at a fold change of 8 and P value of < 0.005. Comparison with 22 previously reported potential biomarkers of metabolic syndrome in patients with psoriasis showed that the levels of 16 biomarkers aligned with the gene regulation observed in the current study. In particular, the REL transcript was upregulated 12-fold (P = 8.16 × 10 −17 ), while the WSB1 transcript was upregulated 9-fold (P = 9.87 × 10 −13 ). Validation showed that REL was also upregulated 2-fold in the polymerase chain reaction, and its protein was expressed at 7.140 ng/mL vs. undetectable levels in the cases (P = 0.048). However, WSB1 was upregulated 2-fold in the polymerase chain reaction compared with controls, and unexpectedly, its protein was undetectable in cases but detectable in controls (P = 0.018). Conclusion:The upregulation of REL and WSB1 was observed in patients with psoriasis and metabolic syndrome, the clinical application of REL and WSB1 as biomarkers needs further validation for potential future implications in clinical practice.

show abstract

Tissue lipocalin-2 in psoriasis: is it a marker of metabolic disturbance or a possible marker of therapeutic efficacy after narrow band ultraviolet B?

Cited by 9 publications

References 21 publications

Neutrophils in Psoriasis

Neutrophils in Psoriasis

Lipocalin 2 Participates in the Epidermal Differentiation and Inflammatory Processes of Psoriasis

Upregulation of REL and WSB1 in patients with psoriasis and metabolic syndrome

Contact Info

Product

Resources

About